| ■ 영문 제목 : Global Retinal Drugs Market 2023-2027 | |
![]() | ■ 상품코드 : IRTNTR70326-23 ■ 조사/발행회사 : Technavio ■ 발행일 : 2023년 1월 최신판(2025년 또는 2026년)은 문의주세요. ■ 페이지수 : 약120 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (24시간 이내) ■ 조사대상 지역 : 북미, 유럽, 아시아, 기타 지역 ■ 산업 분야 : 의약품 |
| Single User (1명 열람용) | USD2,500 ⇒환산₩3,500,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,600,000 | 견적의뢰/주문/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| Technavio사의 본 조사 보고서는 세계의 망막용 약제 시장 규모가 2023년과 2027년 사이에 7,275.79백만 달러에 이르며, 예측 기간 중 연평균 성장률은 6.27%가 될 것으로 예상하고 있습니다. 본 보고서는 세계의 망막용 약제 시장에 대해 광범위한 조사를 실시하여 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 유통 채널별 (병원 약국, 소매 약국, 온라인 약국) 분석, 질환별 (황반 변성증, 당뇨병성 안질환, 기타) 분석, 고객 현황, 지역별 (북미, 유럽, 아시아, 미국, 중국, 독일, 스페인, 캐나다, 기타 지역) 분석, 기업 분석 등의 내용를 수록하고 있습니다. 또한 본 보고서는 Bayer AG, AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Co Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Kubota Corp., MeiraGTx Holdings Plc, Novartis AG, Ocular Therapeutix Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc, Sanofi SA, Santan Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Visufarma 등의 기업 정보를 포함하고 있습니다. ・개요 ・시장 현황 ・시장 규모 예측 ・과거 시장 규모 ・Five Force 분석 ・세계의 망막용 약제 시장 규모 : 유통 채널별 - 병원 약국 채널의 시장 규모 - 소매 약국 채널의 시장 규모 - 온라인 약국 채널의 시장 규모 ・세계의 망막용 약제 시장 규모 : 질환별 - 황반 변성증에 사용되는 망막용 약제의 시장 규모 - 당뇨병성 안질환에 사용되는 망막용 약제의 시장 규모 - 기타 질환에 사용되는 망막용 약제의 시장 규모 ・고객 현황 ・세계의 망막용 약제 시장 규모 : 지역별 - 북미의 망막용 약제 시장 규모 - 유럽의 망막용 약제 시장 규모 - 아시아의 망막용 약제 시장 규모 - 미국의 망막용 약제 시장 규모 - 중국의 망막용 약제 시장 규모 - 독일의 망막용 약제 시장 규모 - 스페인의 망막용 약제 시장 규모 - 캐나다의 망막용 약제 시장 규모 - 기타 지역의 망막용 약제 시장 규모 ・성장 요인/과제/동향 ・기업 현황 ・기업 분석 Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 망막용 약제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 망막용 약제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
2023년부터 2027년까지의 글로벌 망막 약물 시장은 2022년부터 2027년까지 7275.79백만 달러 성장할 것으로 예상되며, 이 기간 동안 연평균 성장률(CAGR)은 6.27%에 이를 것으로 보입니다. 본 보고서는 망막 약물 시장에 대한 종합적인 분석, 시장 규모 및 예측, 트렌드, 성장 동력, 도전 과제, 그리고 약 25개의 공급업체에 대한 분석을 제공합니다. 현재 시장 상황과 최신 동향, 성장 동력 및 전체 시장 환경에 대한 최신 분석이 포함되어 있습니다. 망막 질환의 증가, 첨단 진단 도구의 출현, 환자 지원 프로그램이 시장 성장의 주요 동력으로 작용하고 있습니다.
망막 약물 시장은 유통 채널, 질병 종류, 지역에 따라 세분화됩니다. 유통 채널은 병원 약국, 소매 약국, 온라인 약국으로 나뉘며, 질병 종류는 황반변성, 당뇨병성 눈 질환, 기타로 구분됩니다. 지역적으로는 북미, 유럽, 아시아, 기타 지역(ROW)으로 구분됩니다.
혁신적인 치료법의 개발이 향후 몇 년 간 망막 약물 시장의 성장에 기여할 주요 요인 중 하나로 확인되었습니다. 지속 방출 안구 제형에 대한 수요 증가와 진단 기술의 발전도 시장에서 상당한 수요를 이끌 것으로 예상됩니다.
본 보고서는 망막 약물 시장 규모, 예측, 산업 분석 등의 내용을 포함하고 있으며, 고객이 시장 내 위치를 개선할 수 있도록 돕기 위해 주요 망막 약물 공급업체에 대한 상세한 분석을 제공합니다. 주요 공급업체로는 Bayer AG, AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Co Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Kubota Corp., MeiraGTx Holdings Plc, Novartis AG, Ocular Therapeutix Inc., Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc., Sanofi SA, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Visufarma, Johnson and Johnson Services Inc. 등이 있습니다. 이 보고서에는 시장 성장에 영향을 미칠 향후 트렌드와 도전 과제에 대한 정보도 포함되어 있어, 기업들이 앞으로의 성장 기회를 전략적으로 활용할 수 있도록 돕습니다.
이 연구는 산업의 주요 참가자로부터의 정보와 함께 1차 및 2차 정보를 객관적으로 조합하여 수행되었습니다. 보고서에는 포괄적인 시장 및 공급업체 환경과 주요 공급업체에 대한 분석이 포함되어 있습니다. 또한, 수익, 가격, 경쟁 및 프로모션과 같은 주요 매개변수를 분석하여 시장을 상세하게 설명합니다. 데이터는 포괄적이며 신뢰할 수 있으며, 광범위한 연구 결과입니다. Technavio의 시장 조사 보고서는 완전한 경쟁 환경과 함께 정성적 및 정량적 연구를 통해 정확한 시장 성장을 예측하기 위한 공급업체 선택 방법론 및 분석을 제공합니다.
■ 보고서 목차• 1 요약 • 3 시장 규모 o 표 34: 병원 약국 – 시장 규모 및 전망 차트 2022-2027년 (백만 달러) o 표 55: 당뇨병성 안질환 시장 규모 및 전망 차트 2022-2027 (백만 달러) o 표 59: 기타 – 시장 규모 및 전망 차트 2022-2027 (백만 달러) • 8 고객 현황 표 88: 미국 시장 데이터 표 – 2022-2027년 전년 대비 성장률(%) 9.8 중국 시장 규모 및 전망 2022-2027 표 89: 중국 시장 차트 – 2022-2027년 시장 규모 및 전망(백만 달러) 표 90: 중국 시장 데이터 표 – 2022-2027년 시장 규모 및 전망(백만 달러) 표 91: 중국 시장 차트 – 2022-2027년 전년 대비 성장률(%) 표 92: 중국 시장 데이터 표 – 2022-2027년 전년 대비 성장률(%) 9.9 독일 시장 규모 및 전망 2022-2027 표 93: 독일 시장 차트 – 시장 규모 및 전망 2022-2027년 (백만 달러) o 표 152: 노바티스(Novartis AG) – 주요 제공 서비스 첨부 자료: 표 1: 요약 – 시장 개요 차트 표 61: 기타 – 2022-2027년 전년 대비 성장률(%) 차트 첨부자료 152: 노바티스(Novartis AG) – 주요 상품 및 서비스 첨부자료 162: 화이자(Pfizer Inc.) – 주요 뉴스 첨부자료 166: 리제네론 파마슈티컬스(Regeneron Pharmaceuticals Inc.) – 주요 서비스 o 1.1 Market overview o Exhibit 01: Executive Summary - Chart on Market Overview o Exhibit 02: Executive Summary - Data Table on Market Overview o Exhibit 03: Executive Summary - Chart on Global Market Characteristics o Exhibit 04: Executive Summary - Chart on Market by Geography o Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel o Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication o Exhibit 07: Executive Summary - Chart on Incremental Growth o Exhibit 08: Executive Summary - Data Table on Incremental Growth o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning • 2 Market Landscape o 2.1 Market ecosystem o Exhibit 10: Parent market o Exhibit 11: Market Characteristics • 3 Market Sizing o 3.1 Market definition o Exhibit 12: Offerings of vendors included in the market definition o 3.2 Market segment analysis o Exhibit 13: Market segments o 3.3 Market size 2022 o 3.4 Market outlook: Forecast for 2022-2027 o Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) • 4 Historic Market Size o 4.1 Global retinal drugs market 2017 - 2021 o Exhibit 18: Historic Market Size - Data Table on Global retinal drugs market 2017 - 2021 ($ million) o 4.2 Ditribution channel Segment Analysis 2017 - 2021 o Exhibit 19: Historic Market Size - Ditribution channel Segment 2017 - 2021 ($ million) o 4.3 Indication Segment Analysis 2017 - 2021 o Exhibit 20: Historic Market Size - Indication Segment 2017 - 2021 ($ million) o 4.4 Geography Segment Analysis 2017 - 2021 o Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) o 4.5 Country Segment Analysis 2017 - 2021 o Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million) • 5 Five Forces Analysis o 5.1 Five forces summary o Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 o 5.2 Bargaining power of buyers o Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 o 5.3 Bargaining power of suppliers o Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 o 5.4 Threat of new entrants o Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027 o 5.5 Threat of substitutes o Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027 o 5.6 Threat of rivalry o Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027 o 5.7 Market condition o Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 • 6 Market Segmentation by Distribution Channel o 6.1 Market segments o Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%) o Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%) o 6.2 Comparison by Distribution Channel o Exhibit 32: Chart on Comparison by Distribution Channel o Exhibit 33: Data Table on Comparison by Distribution Channel o 6.3 Hospital pharmacy - Market size and forecast 2022-2027 o Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million) o Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million) o Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%) o Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%) o 6.4 Retail pharmacy - Market size and forecast 2022-2027 o Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million) o Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million) o Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%) o Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%) o 6.5 Online pharmacy - Market size and forecast 2022-2027 o Exhibit 42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million) o Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million) o Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%) o Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%) o 6.6 Market opportunity by Distribution Channel o Exhibit 46: Market opportunity by Distribution Channel ($ million) • 7 Market Segmentation by Indication o 7.1 Market segments o Exhibit 47: Chart on Indication - Market share 2022-2027 (%) o Exhibit 48: Data Table on Indication - Market share 2022-2027 (%) o 7.2 Comparison by Indication o Exhibit 49: Chart on Comparison by Indication o Exhibit 50: Data Table on Comparison by Indication o 7.3 Macular degeneration - Market size and forecast 2022-2027 o Exhibit 51: Chart on Macular degeneration - Market size and forecast 2022-2027 ($ million) o Exhibit 52: Data Table on Macular degeneration - Market size and forecast 2022-2027 ($ million) o Exhibit 53: Chart on Macular degeneration - Year-over-year growth 2022-2027 (%) o Exhibit 54: Data Table on Macular degeneration - Year-over-year growth 2022-2027 (%) o 7.4 Diabetic eye disease - Market size and forecast 2022-2027 o Exhibit 55: Chart on Diabetic eye disease - Market size and forecast 2022-2027 ($ million) o Exhibit 56: Data Table on Diabetic eye disease - Market size and forecast 2022-2027 ($ million) o Exhibit 57: Chart on Diabetic eye disease - Year-over-year growth 2022-2027 (%) o Exhibit 58: Data Table on Diabetic eye disease - Year-over-year growth 2022-2027 (%) o 7.5 Others - Market size and forecast 2022-2027 o Exhibit 59: Chart on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 ($ million) o Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%) o Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%) o 7.6 Market opportunity by Indication o Exhibit 63: Market opportunity by Indication ($ million) • 8 Customer Landscape o 8.1 Customer landscape overview o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria • 9 Geographic Landscape o 9.1 Geographic segmentation o Exhibit 65: Chart on Market share by geography 2022-2027 (%) o Exhibit 66: Data Table on Market share by geography 2022-2027 (%) o 9.2 Geographic comparison o Exhibit 67: Chart on Geographic comparison o Exhibit 68: Data Table on Geographic comparison o 9.3 North America - Market size and forecast 2022-2027 o Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million) o Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%) o Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%) o 9.4 Europe - Market size and forecast 2022-2027 o Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) o Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%) o Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%) o 9.5 Asia - Market size and forecast 2022-2027 o Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) o Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%) o Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%) o 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 o Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) o Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) o 9.7 US - Market size and forecast 2022-2027 o Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million) o Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million) o Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%) o Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%) o 9.8 China - Market size and forecast 2022-2027 o Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million) o Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million) o Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%) o Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%) o 9.9 Germany - Market size and forecast 2022-2027 o Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million) o Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%) o Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%) o 9.10 Spain - Market size and forecast 2022-2027 o Exhibit 97: Chart on Spain - Market size and forecast 2022-2027 ($ million) o Exhibit 98: Data Table on Spain - Market size and forecast 2022-2027 ($ million) o Exhibit 99: Chart on Spain - Year-over-year growth 2022-2027 (%) o Exhibit 100: Data Table on Spain - Year-over-year growth 2022-2027 (%) o 9.11 Canada - Market size and forecast 2022-2027 o Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 ($ million) o Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%) o Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%) o 9.12 Market opportunity by geography o Exhibit 105: Market opportunity by geography ($ million) • 10 Drivers, Challenges, and Trends o 10.1 Market drivers o 10.2 Market challenges o 10.3 Impact of drivers and challenges o Exhibit 106: Impact of drivers and challenges in 2022 and 2027 o 10.4 Market trends • 11 Vendor Landscape o 11.1 Overview o 11.2 Vendor landscape o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation o 11.3 Landscape disruption o Exhibit 108: Overview on factors of disruption o 11.4 Industry risks o Exhibit 109: Impact of key risks on business • 12 Vendor Analysis o 12.1 Vendors covered o Exhibit 110: Vendors covered o 12.2 Market positioning of vendors o Exhibit 111: Matrix on vendor position and classification o 12.3 AbbVie Inc. o Exhibit 112: AbbVie Inc. - Overview o Exhibit 113: AbbVie Inc. - Product / Service o Exhibit 114: AbbVie Inc. - Key news o Exhibit 115: AbbVie Inc. - Key offerings o 12.4 Alcon Inc. o Exhibit 116: Alcon Inc. - Overview o Exhibit 117: Alcon Inc. - Business segments o Exhibit 118: Alcon Inc. - Key offerings o Exhibit 119: Alcon Inc. - Segment focus o 12.5 Alimera Sciences Inc. o Exhibit 120: Alimera Sciences Inc. - Overview o Exhibit 121: Alimera Sciences Inc. - Product / Service o Exhibit 122: Alimera Sciences Inc. - Key offerings o 12.6 Bausch Health Co Inc. o Exhibit 123: Bausch Health Co Inc. - Overview o Exhibit 124: Bausch Health Co Inc. - Business segments o Exhibit 125: Bausch Health Co Inc. - Key news o Exhibit 126: Bausch Health Co Inc. - Key offerings o Exhibit 127: Bausch Health Co Inc. - Segment focus o 12.7 Bayer AG o Exhibit 128: Bayer AG - Overview o Exhibit 129: Bayer AG - Business segments o Exhibit 130: Bayer AG - Key news o Exhibit 131: Bayer AG - Key offerings o Exhibit 132: Bayer AG - Segment focus o 12.8 Bristol Myers Squibb Co. o Exhibit 133: Bristol Myers Squibb Co. - Overview o Exhibit 134: Bristol Myers Squibb Co. - Product / Service o Exhibit 135: Bristol Myers Squibb Co. - Key news o Exhibit 136: Bristol Myers Squibb Co. - Key offerings o 12.9 F. Hoffmann La Roche Ltd. o Exhibit 137: F. Hoffmann La Roche Ltd. - Overview o Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments o Exhibit 139: F. Hoffmann La Roche Ltd. - Key news o Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings o Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus o 12.10 Johnson and Johnson Services Inc. o Exhibit 142: Johnson and Johnson Services Inc. - Overview o Exhibit 143: Johnson and Johnson Services Inc. - Business segments o Exhibit 144: Johnson and Johnson Services Inc. - Key news o Exhibit 145: Johnson and Johnson Services Inc. - Key offerings o Exhibit 146: Johnson and Johnson Services Inc. - Segment focus o 12.11 MeiraGTx Holdings Plc o Exhibit 147: MeiraGTx Holdings Plc - Overview o Exhibit 148: MeiraGTx Holdings Plc - Product / Service o Exhibit 149: MeiraGTx Holdings Plc - Key offerings o 12.12 Novartis AG o Exhibit 150: Novartis AG - Overview o Exhibit 151: Novartis AG - Business segments o Exhibit 152: Novartis AG - Key offerings o Exhibit 153: Novartis AG - Segment focus o 12.13 Ocular Therapeutix Inc. o Exhibit 154: Ocular Therapeutix Inc. - Overview o Exhibit 155: Ocular Therapeutix Inc. - Product / Service o Exhibit 156: Ocular Therapeutix Inc. - Key offerings o 12.14 Oxurion NV o Exhibit 157: Oxurion NV - Overview o Exhibit 158: Oxurion NV - Product / Service o Exhibit 159: Oxurion NV - Key offerings o 12.15 Pfizer Inc. o Exhibit 160: Pfizer Inc. - Overview o Exhibit 161: Pfizer Inc. - Product / Service o Exhibit 162: Pfizer Inc. - Key news o Exhibit 163: Pfizer Inc. - Key offerings o 12.16 Regeneron Pharmaceuticals Inc. o Exhibit 164: Regeneron Pharmaceuticals Inc. - Overview o Exhibit 165: Regeneron Pharmaceuticals Inc. - Product / Service o Exhibit 166: Regeneron Pharmaceuticals Inc. - Key offerings o 12.17 Sanofi SA o Exhibit 167: Sanofi SA - Overview o Exhibit 168: Sanofi SA - Business segments o Exhibit 169: Sanofi SA - Key news o Exhibit 170: Sanofi SA - Key offerings o Exhibit 171: Sanofi SA - Segment focus • 13 Appendix o 13.1 Scope of the report o 13.2 Inclusions and exclusions checklist o Exhibit 172: Inclusions checklist o Exhibit 173: Exclusions checklist o 13.3 Currency conversion rates for US$ o Exhibit 174: Currency conversion rates for US$ o 13.4 Research methodology o Exhibit 175: Research methodology o Exhibit 176: Validation techniques employed for market sizing o Exhibit 177: Information sources o 13.5 List of abbreviations o Exhibit 178: List of abbreviations Exhibits: Exhibits1: Executive Summary - Chart on Market Overview Exhibits2: Executive Summary - Data Table on Market Overview Exhibits3: Executive Summary - Chart on Global Market Characteristics Exhibits4: Executive Summary - Chart on Market by Geography Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel Exhibits6: Executive Summary - Chart on Market Segmentation by Indication Exhibits7: Executive Summary - Chart on Incremental Growth Exhibits8: Executive Summary - Data Table on Incremental Growth Exhibits9: Executive Summary - Chart on Vendor Market Positioning Exhibits10: Parent market Exhibits11: Market Characteristics Exhibits12: Offerings of vendors included in the market definition Exhibits13: Market segments Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) Exhibits18: Historic Market Size - Data Table on Global retinal drugs market 2017 - 2021 ($ million) Exhibits19: Historic Market Size - Ditribution channel Segment 2017 - 2021 ($ million) Exhibits20: Historic Market Size - Indication Segment 2017 - 2021 ($ million) Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million) Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million) Exhibits23: Five forces analysis - Comparison between 2022 and 2027 Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027 Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027 Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027 Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027 Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027 Exhibits29: Chart on Market condition - Five forces 2022 and 2027 Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%) Exhibits32: Chart on Comparison by Distribution Channel Exhibits33: Data Table on Comparison by Distribution Channel Exhibits34: Chart on Hospital pharmacy - Market size and forecast 2022-2027 ($ million) Exhibits35: Data Table on Hospital pharmacy - Market size and forecast 2022-2027 ($ million) Exhibits36: Chart on Hospital pharmacy - Year-over-year growth 2022-2027 (%) Exhibits37: Data Table on Hospital pharmacy - Year-over-year growth 2022-2027 (%) Exhibits38: Chart on Retail pharmacy - Market size and forecast 2022-2027 ($ million) Exhibits39: Data Table on Retail pharmacy - Market size and forecast 2022-2027 ($ million) Exhibits40: Chart on Retail pharmacy - Year-over-year growth 2022-2027 (%) Exhibits41: Data Table on Retail pharmacy - Year-over-year growth 2022-2027 (%) Exhibits42: Chart on Online pharmacy - Market size and forecast 2022-2027 ($ million) Exhibits43: Data Table on Online pharmacy - Market size and forecast 2022-2027 ($ million) Exhibits44: Chart on Online pharmacy - Year-over-year growth 2022-2027 (%) Exhibits45: Data Table on Online pharmacy - Year-over-year growth 2022-2027 (%) Exhibits46: Market opportunity by Distribution Channel ($ million) Exhibits47: Chart on Indication - Market share 2022-2027 (%) Exhibits48: Data Table on Indication - Market share 2022-2027 (%) Exhibits49: Chart on Comparison by Indication Exhibits50: Data Table on Comparison by Indication Exhibits51: Chart on Macular degeneration - Market size and forecast 2022-2027 ($ million) Exhibits52: Data Table on Macular degeneration - Market size and forecast 2022-2027 ($ million) Exhibits53: Chart on Macular degeneration - Year-over-year growth 2022-2027 (%) Exhibits54: Data Table on Macular degeneration - Year-over-year growth 2022-2027 (%) Exhibits55: Chart on Diabetic eye disease - Market size and forecast 2022-2027 ($ million) Exhibits56: Data Table on Diabetic eye disease - Market size and forecast 2022-2027 ($ million) Exhibits57: Chart on Diabetic eye disease - Year-over-year growth 2022-2027 (%) Exhibits58: Data Table on Diabetic eye disease - Year-over-year growth 2022-2027 (%) Exhibits59: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibits60: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibits61: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibits62: Data Table on Others - Year-over-year growth 2022-2027 (%) Exhibits63: Market opportunity by Indication ($ million) Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria Exhibits65: Chart on Market share by geography 2022-2027 (%) Exhibits66: Data Table on Market share by geography 2022-2027 (%) Exhibits67: Chart on Geographic comparison Exhibits68: Data Table on Geographic comparison Exhibits69: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibits70: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibits71: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibits72: Data Table on North America - Year-over-year growth 2022-2027 (%) Exhibits73: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibits74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibits75: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibits76: Data Table on Europe - Year-over-year growth 2022-2027 (%) Exhibits77: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibits78: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibits79: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibits80: Data Table on Asia - Year-over-year growth 2022-2027 (%) Exhibits81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibits83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibits85: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibits86: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibits87: Chart on US - Year-over-year growth 2022-2027 (%) Exhibits88: Data Table on US - Year-over-year growth 2022-2027 (%) Exhibits89: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibits90: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibits91: Chart on China - Year-over-year growth 2022-2027 (%) Exhibits92: Data Table on China - Year-over-year growth 2022-2027 (%) Exhibits93: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibits94: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibits95: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibits96: Data Table on Germany - Year-over-year growth 2022-2027 (%) Exhibits97: Chart on Spain - Market size and forecast 2022-2027 ($ million) Exhibits98: Data Table on Spain - Market size and forecast 2022-2027 ($ million) Exhibits99: Chart on Spain - Year-over-year growth 2022-2027 (%) Exhibits100: Data Table on Spain - Year-over-year growth 2022-2027 (%) Exhibits101: Chart on Canada - Market size and forecast 2022-2027 ($ million) Exhibits102: Data Table on Canada - Market size and forecast 2022-2027 ($ million) Exhibits103: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibits104: Data Table on Canada - Year-over-year growth 2022-2027 (%) Exhibits105: Market opportunity by geography ($ million) Exhibits106: Impact of drivers and challenges in 2022 and 2027 Exhibits107: Overview on Criticality of inputs and Factors of differentiation Exhibits108: Overview on factors of disruption Exhibits109: Impact of key risks on business Exhibits110: Vendors covered Exhibits111: Matrix on vendor position and classification Exhibits112: AbbVie Inc. - Overview Exhibits113: AbbVie Inc. - Product / Service Exhibits114: AbbVie Inc. - Key news Exhibits115: AbbVie Inc. - Key offerings Exhibits116: Alcon Inc. - Overview Exhibits117: Alcon Inc. - Business segments Exhibits118: Alcon Inc. - Key offerings Exhibits119: Alcon Inc. - Segment focus Exhibits120: Alimera Sciences Inc. - Overview Exhibits121: Alimera Sciences Inc. - Product / Service Exhibits122: Alimera Sciences Inc. - Key offerings Exhibits123: Bausch Health Co Inc. - Overview Exhibits124: Bausch Health Co Inc. - Business segments Exhibits125: Bausch Health Co Inc. - Key news Exhibits126: Bausch Health Co Inc. - Key offerings Exhibits127: Bausch Health Co Inc. - Segment focus Exhibits128: Bayer AG - Overview Exhibits129: Bayer AG - Business segments Exhibits130: Bayer AG - Key news Exhibits131: Bayer AG - Key offerings Exhibits132: Bayer AG - Segment focus Exhibits133: Bristol Myers Squibb Co. - Overview Exhibits134: Bristol Myers Squibb Co. - Product / Service Exhibits135: Bristol Myers Squibb Co. - Key news Exhibits136: Bristol Myers Squibb Co. - Key offerings Exhibits137: F. Hoffmann La Roche Ltd. - Overview Exhibits138: F. Hoffmann La Roche Ltd. - Business segments Exhibits139: F. Hoffmann La Roche Ltd. - Key news Exhibits140: F. Hoffmann La Roche Ltd. - Key offerings Exhibits141: F. Hoffmann La Roche Ltd. - Segment focus Exhibits142: Johnson and Johnson Services Inc. - Overview Exhibits143: Johnson and Johnson Services Inc. - Business segments Exhibits144: Johnson and Johnson Services Inc. - Key news Exhibits145: Johnson and Johnson Services Inc. - Key offerings Exhibits146: Johnson and Johnson Services Inc. - Segment focus Exhibits147: MeiraGTx Holdings Plc - Overview Exhibits148: MeiraGTx Holdings Plc - Product / Service Exhibits149: MeiraGTx Holdings Plc - Key offerings Exhibits150: Novartis AG - Overview Exhibits151: Novartis AG - Business segments Exhibits152: Novartis AG - Key offerings Exhibits153: Novartis AG - Segment focus Exhibits154: Ocular Therapeutix Inc. - Overview Exhibits155: Ocular Therapeutix Inc. - Product / Service Exhibits156: Ocular Therapeutix Inc. - Key offerings Exhibits157: Oxurion NV - Overview Exhibits158: Oxurion NV - Product / Service Exhibits159: Oxurion NV - Key offerings Exhibits160: Pfizer Inc. - Overview Exhibits161: Pfizer Inc. - Product / Service Exhibits162: Pfizer Inc. - Key news Exhibits163: Pfizer Inc. - Key offerings Exhibits164: Regeneron Pharmaceuticals Inc. - Overview Exhibits165: Regeneron Pharmaceuticals Inc. - Product / Service Exhibits166: Regeneron Pharmaceuticals Inc. - Key offerings Exhibits167: Sanofi SA - Overview Exhibits168: Sanofi SA - Business segments Exhibits169: Sanofi SA - Key news Exhibits170: Sanofi SA - Key offerings Exhibits171: Sanofi SA - Segment focus Exhibits172: Inclusions checklist Exhibits173: Exclusions checklist Exhibits174: Currency conversion rates for US$ Exhibits175: Research methodology Exhibits176: Validation techniques employed for market sizing Exhibits177: Information sources Exhibits178: List of abbreviations |
| ※참고 정보 망막용 약제는 눈의 망막에 영향을 미치는 질환을 치료하거나 예방하기 위해 개발된 약물입니다. 망막은 시각 정보의 수집과 처리에 중요한 역할을 하며, 이곳에서 발생하는 다양한 질환들은 시력 손실로 이어질 수 있습니다. 따라서 이러한 질환을 효과적으로 치료하기 위한 약물 개발이 중요하며, 최근 몇 년간 망막용 약제의 연구와 발전이 크게 이루어졌습니다. 망막용 약제의 주요 개념은 망막의 특정 질환, 예를 들어 황반변성, 당뇨병성 망막병증, 망막정맥폐쇄 등과 같은 질환에 초점을 맞추고 있습니다. 이러한 약제는 망막의 염증, 세포 사멸, 신생혈관 형성 등 다양한 병리학적 과정에 작용하여 질환의 진행을 억제하거나 증상을 개선하는 데 도움을 줍니다. 또한, 약물의 적절한 배출과 작용 시간을 고려하여 다양한 투여 경로(예: 경구, 주사, 안구내 유리체 주사 등)를 통해 효과적으로 망막에 도달할 수 있도록 설계됩니다. 망막용 약제의 종류는 크게 세 가지로 나눌 수 있습니다. 첫째, 항염증제입니다. 이들은 망막의 염증 반응을 억제하여, 염증으로 인한 세포 손상을 예방합니다. 스테로이드 계열의 약물이 그 예로, 염증성 질환에서 많이 사용됩니다. 둘째, 항신생혈관제입니다. 이들은 비정상적인 혈관 형성을 저지하여, 주로 나이와 관련된 황반변성과 같은 질환에 효과적입니다. 이러한 약물들은 혈관 내피 성장인자(VEGF)를 억제하여 비정상적인 혈관 성장과 누출을 방지합니다. 셋째, 유전자 치료제입니다. 최신 기술을 이용하여 특정 유전적 결함을 교정하거나 특정 단백질을 정상적으로 발현시키도록 하는 접근법을 활용합니다. 이러한 접근법은 특별한 유전적 질환에 대해 높은 치료 효과를 보일 수 있습니다. 망막용 약제의 주요 용도는 시력을 보호하고 개선하는 것입니다. 특히, 당뇨병성 망막병증에서 혈당 조절이 지연할 때 사용되어 망막의 손상을 줄이며, 여성 고령자에서 흔히 발생하는 황반변성 치료에도 필수적입니다. 이 외에도, 망막정맥폐쇄로 인한 혈류 장애를 해소하고 시각 기능을 회복시키는 데 기여합니다. 망막용 약물은 안전성과 효과를 고려하여 임상시험을 통해 입증되며, 개별 환자의 특성에 맞춘 적절한 치료 계획을 수립하는 것이 중요합니다. 최근 몇 년 사이에 망막용 약제와 관련된 기술이 발전하고 있습니다. 예를 들어, 형광 안저 촬영, Optical Coherence Tomography(OCT) 등의 진단 기술이 발달하면서 질환의 조기 발견과 치료 계획의 수립이 용이해졌습니다. 또한, 약물 전달 시스템의 혁신을 통해 약물이 망막에 더욱 효과적으로 도달할 수 있도록 하는 연구도 진행 중입니다. 이러한 기술들은 망막 질환 치료의 효율성을 높이는 데 기여하고 있으며, 향후 보다 정밀한 치료가 가능해질 것으로 예상됩니다. 총합적으로, 망막용 약제는 망막 질환 치료의 핵심 요소로 자리잡고 있으며, 다양한 종류의 약물과 혁신적인 기술의 발전으로 인해 환자의 시력을 보존하고 개선하는 데 큰 역할을 하고 있습니다. 앞으로도 더 많은 연구와 임상 응용이 이루어질 것으로 기대됩니다. |
| ※본 조사보고서 [세계의 망막용 약제 시장 (2023년~2027년)] (코드 : IRTNTR70326-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 망막용 약제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |

